Key facts
- This page summarizes Robert E. George's Form 4 filing for Moleculin Biotech, Inc. (MBRX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 27 Dec 2023, 07:31.
Robert E. George - 26 Dec 2023 Form 4 Insider Report for Moleculin Biotech, Inc. (MBRX)
- Reporting relationship
- Director
- Issuer ticker
- MBRX
- Reported as of
- 26 Dec 2023
- Net transaction value
- +$10,000
- SEC form
- 4
- Accepted by SEC
- 27 Dec 2023, 07:31:57 UTC
- Prior SEC filing
- 26 May 2023
- Next SEC filing
- 06 Nov 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan P. Foster by Power of Attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert E. George filed Form 4 for Moleculin Biotech, Inc. (MBRX) on 27 Dec 2023.
Change
- Previous filing in this sequence was filed on 26 May 2023.
- Current net transaction value: +$10,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MBRX
transaction
Common Stock
Purchase
- Transaction value
- $10,000
- Shares
- +14,493
- Change %
- +8678%
- Price
- $0.6900
- Shares after
- 14,660
- Date
- 26 Dec 2023
- Ownership
- Direct
* marks a reported price that did not pass the local price check.